gsk-j4 has been researched along with Neoplasms* in 2 studies
1 review(s) available for gsk-j4 and Neoplasms
Article | Year |
---|---|
GSK-J4: An H3K27 histone demethylase inhibitor, as a potential anti-cancer agent.
Aberrant epigenetic modifications are emerging as potent drivers of tumor initiation and progression. The deregulation of H3K27me3 marks has shown to play an important role in cancer progression in several cancers. The H3K27me3 mark is associated with gene silencing. The reversible nature of these epigenetic aberrations makes them an important target for treating cancer. GSK-J4 is a histone demethylase inhibitor that inhibits the JMJD3/UTX enzyme, which results in the upregulation of H3K27me3 levels. In this review, the anti-cancer properties of GSK-J4 have been summarized, the various molecular pathways targeted, in-vivo studies, and drug combination studies in different cancer models. GSK-J4 targeted pathways like apoptosis, cell cycle, invasion, migration, DNA damage repair, metabolism, oxidative stress, stemness, etc. GSK-J4 is a promising candidate alone and in combination with other conventional anti-cancer drugs against different cancer types. Topics: Benzazepines; Histone Demethylases; Histones; Humans; Jumonji Domain-Containing Histone Demethylases; Neoplasms | 2023 |
1 other study(ies) available for gsk-j4 and Neoplasms
Article | Year |
---|---|
SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade.
Despite the genetic inactivation of SMARCA4, a core component of the SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient tumours. Here, we show that, unlike the cells with activated MYC oncogene, cells with SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to the aberrant accumulation of H3K27me3. SMARCA4-mutant cells also show an impaired transactivation and significantly reduced levels of the histone demethylases KDM6A/UTX and KDM6B/JMJD3, and a strong dependency on these histone demethylases, so that its inhibition compromises cell viability. Administering the KDM6 inhibitor GSK-J4 to mice orthotopically implanted with SMARCA4-mutant lung cancer cells or primary small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT), had strong anti-tumour effects. In this work we highlight the vulnerability of KDM6 inhibitors as a characteristic that could be exploited for treating SMARCA4-mutant cancer patients. Topics: Animals; Antineoplastic Agents; Benzazepines; Cell Line, Tumor; Cell Survival; DNA Helicases; Drug Resistance, Neoplasm; Gene Expression; Histone Deacetylase Inhibitors; Histone Demethylases; Histones; Humans; Jumonji Domain-Containing Histone Demethylases; Mice; Neoplasms; Nuclear Proteins; Pyrimidines; Transcription Factors; Transcriptional Activation | 2021 |